Clomid is intended for selected women who need help achieving ovulation and for some men assessed by a reproductive endocrinology specialist. Its active ingredient, clomifene citrate, changes…
Clomid is intended for selected women who need help achieving ovulation and for some men assessed by a reproductive endocrinology specialist. Its active ingredient, clomifene citrate, changes hypothalamic hormone signalling so the body may increase the hormonal signals that support ovulation or testosterone production.
Women with diagnosed ovulatory infertility may be prescribed Clomid after assessment of the underlying cause. Clomid contains clomifene citrate, which alters hypothalamic hormone signalling to encourage ovulation. It is also used off-label in some male reproductive endocrinology settings, including recovery after hormone suppression.
Clomifene is used to induce ovulation in selected women who do not ovulate regularly. Anovulation may occur with polycystic ovary syndrome, sometimes called PCOS, although PCOS is only one possible cause of fertility problems.
Treatment starts after an assessment of the menstrual history, pregnancy status, ovarian reserve and other relevant factors. Clinicians may also assess thyroid function, prolactin, androgen levels, tubal patency and semen parameters. These checks help prevent clomifene being used when another treatment route is more appropriate.
Monitoring can include:
The treatment goal is usually one predictable ovulation rather than the production of many follicles. Ovarian stimulation can increase the chance of twins or higher-order pregnancy, so clinicians balance the response against this risk.
Clomifene should not be used during pregnancy. A pregnancy test or clinical confirmation of cycle status is required before a new treatment course begins. The World Health Organization identifies infertility as a condition requiring investigation of both partners rather than treatment of ovulation alone [2].
Clomid contains clomifene citrate, also called clomiphene citrate, in a tablet. Clomifene is a selective oestrogen receptor modulator, or SERM. In the UK, clomifene is a prescription-only treatment used mainly for ovulation induction under specialist supervision. Its use is guided by the cause of infertility and the patient’s response. Treatment decisions should account for monitoring needs and potential adverse effects.
The tablet acts through hormone feedback rather than supplying reproductive hormones directly. Its clinical use depends on the diagnosis, ovarian function, semen analysis where relevant, and the treatment goal.
Each tablet contains clomifene citrate. The active substance is absorbed orally and acts on oestrogen receptors in the hypothalamus and pituitary gland. The formulation is intended to be swallowed as a tablet.
Clomifene is not suitable for every cause of infertility. It cannot correct blocked fallopian tubes, severe ovarian failure, or a male-factor problem without addressing that problem separately.
Clomifene partially blocks oestrogen feedback at the hypothalamus. The brain then receives a weaker signal that circulating oestrogen is sufficient, which can increase pulsatile gonadotrophin-releasing hormone activity. The pituitary may release more follicle-stimulating hormone, or FSH, and luteinising hormone, or LH.
FSH supports follicular development in the ovary. A mature follicle can then produce oestradiol and release an egg during ovulation. The same hypothalamic-pituitary-gonadal pathway explains why clomifene has attracted interest in male hypogonadism and post-cycle therapy, although those uses require specialist assessment and are not the main licensed fertility indication.
The drug does not directly provide testosterone. In men with functioning testes, increased LH can stimulate Leydig cells to produce more testosterone, while FSH supports Sertoli-cell activity and sperm production. The response depends on the cause of low testosterone and the condition of the testes.
The MHRA and European Medicines Agency describe clomifene’s action and risks within regulatory product information, including visual symptoms, ovarian enlargement and the need to exclude pregnancy before treatment [1].
Clomid is an oral tablet. The regimen for the chosen strength must be confirmed with a healthcare professional before starting, because the appropriate course depends on the indication, cycle history, ovarian response, hormone results and treatment plan.
For female fertility treatment, clomifene is taken during a defined part of the menstrual cycle. The fertility clinician determines the starting day, number of treatment days and whether another course is appropriate. Repeated or prolonged use requires review because ovarian response and cumulative risks matter.
For male reproductive-endocrine use, there is no single suitable regimen for every patient. The prescriber may use blood-test results, symptoms, semen analysis and the response to treatment to determine whether the approach should continue.
Practical administration points include:
Clomifene does not need to be taken as a long-term daily hormone replacement. Its use is usually linked to a specific cycle or endocrine treatment plan.
Clomifene, tamoxifen, anastrozole and HCG affect reproductive hormone physiology through different pathways. Their selection depends on laboratory findings, fertility plans, symptoms and the cause of hormonal suppression.
| Treatment | Main pharmacological action | Typical clinical focus |
|---|---|---|
| Clomifene | SERM; reduces oestrogen feedback at the hypothalamus | Ovulation induction; selected specialist male-hormone cases |
| Tamoxifen | SERM with tissue-specific oestrogen-receptor activity | Selected reproductive-endocrine protocols |
| Anastrozole | Aromatase inhibitor; reduces conversion of androgens to oestrogens | Selected cases of raised oestradiol under specialist monitoring |
HCG is not a SERM. It mimics LH and acts directly on testicular LH receptors. It may be used in specialist reproductive endocrinology, yet it requires a different monitoring strategy from clomifene.
Aromatase inhibition is not automatically preferable when oestradiol is elevated. Excessive reduction of oestradiol can affect bone health, joints, mood and sexual function. Clomifene can raise testosterone in some men, but it may also cause visual symptoms, mood changes or oestrogen-related symptoms.
Several practical mistakes can reduce benefit or delay recognition of harm:
One detail patients often miss is that a normal-looking menstrual bleed does not prove ovulation. Progesterone testing or ultrasound may be needed to confirm the response.
Another is that clomifene can produce symptoms from altered oestrogen signalling even when testosterone rises. New breast tenderness, mood change or headaches should be documented rather than dismissed.
Clomid is not suitable for everyone. This treatment is not for you if you have active liver disease, unexplained abnormal liver-function results, uncontrolled thyroid or adrenal disease, a pituitary tumour requiring different management, ovarian failure that cannot respond to stimulation, or pregnancy.
It is also unsuitable where abnormal uterine bleeding has not been investigated. A pelvic mass or ovarian cyst unrelated to PCOS requires assessment before ovulation induction.
Specific points requiring clinical review include:
Clomifene may interact pharmacodynamically with testosterone, HCG, anabolic steroids, aromatase inhibitors and other fertility treatments. The concern is not always a simple chemical interaction; combined hormone effects can alter blood results, fertility outcomes and adverse-event risk.
The NHS, MHRA and specialist fertility services also emphasise pregnancy exclusion and assessment of visual symptoms before further treatment. The FDA prescribing information describes contraindications and warnings that support these precautions [4].
This treatment may not be right for you if you are pregnant, have unexplained bleeding, a liver problem, an ovarian cyst or severe ovarian failure. Speak to the prescriber before treatment if you have uncontrolled thyroid or adrenal disease, previous serious mood problems, visual symptoms, or take medicines that affect hormones or liver function.
Clomifene can cause adverse effects because it changes oestrogen signalling in several tissues. Some effects are temporary, while others require prompt assessment.
| Effect category | Examples | Required response |
|---|---|---|
| Common or treatment-related | Hot flushes, headache, nausea, breast discomfort, mood changes | Report persistent or troublesome symptoms |
| Reproductive and pelvic | Ovarian enlargement, pelvic discomfort, ovarian cysts, multiple ovulation | Seek assessment for significant pain or swelling |
| Urgent | Blurred vision, flashes, spots, reduced visual field, severe abdominal pain or shortness of breath | Stop further doses until urgently assessed |
Visual disturbances deserve special attention. They may begin as blurred vision, light sensitivity, flashes or spots and can become persistent if treatment continues. A person who develops these symptoms should not continue taking tablets while waiting for a routine appointment.
Mood changes can include irritability, anxiety or low mood. Sleep disruption may make these symptoms more noticeable. People with a history of severe mood disorder should discuss previous episodes before treatment starts.
Ovarian hyperstimulation syndrome is more commonly associated with injectable gonadotrophins, but ovarian enlargement and cyst formation can occur with clomifene. Severe abdominal swelling, rapid weight increase, vomiting or breathlessness needs urgent medical evaluation.
Clomifene can also increase the likelihood of a multiple pregnancy. This is a clinical risk rather than a treatment benefit, because twin or higher-order pregnancy carries additional obstetric risks. The EMA product information describes these reproductive and visual safety concerns [3].
In clinical practice, doctors usually treat clomifene as a cycle-based hormone intervention rather than a general fertility booster. The starting decision follows diagnosis, not a desire to raise a single hormone value.
A fertility specialist may say: “The target is ovulation with the lowest reasonable exposure, followed by evidence that ovulation occurred.” That approach reduces unnecessary repeat courses and identifies people who need another fertility pathway.
An endocrinologist assessing male hypogonadism will usually distinguish low testosterone caused by secondary hormonal suppression from primary testicular failure. Clomifene may have a physiological rationale in the first situation, while it is less likely to help when the testes cannot respond adequately to LH and FSH.
Doctors also consider the patient’s priorities. Someone trying to preserve fertility may need a different strategy from someone seeking symptom relief alone, because standard testosterone replacement can suppress sperm production.
Clomifene can cause visual disturbances, headache, dizziness or mood changes that impair driving and machinery work. The MHRA’s safety approach in 2026 remains consistent with stopping activity that requires clear vision if flashes, spots or blurred vision occur. Do not drive until symptoms have resolved and a clinician has assessed whether further treatment is appropriate.
There is no universally superior time of day for every patient. A fertility clinician may choose a consistent time that fits the cycle plan, while the EMA product information (2023) supports taking the prescribed course as directed rather than changing timing independently. Taking it at a regular time can make missed doses less likely, especially when headaches or nausea make the treatment harder to remember.
Alcohol is not known to provide a therapeutic benefit during clomifene treatment and may worsen headache, dizziness, nausea or poor sleep. The WHO’s reproductive-health guidance in 2026 supports avoiding factors that make treatment monitoring or early pregnancy assessment less clear. Avoid alcohol if you feel dizzy, have visual symptoms, are trying to conceive or are taking other hormone-active medicines.
Pregnancy rules out clomifene use because the treatment is intended to stimulate ovulation before conception. The MHRA product information also lists liver disease, unexplained abnormal uterine bleeding and ovarian cysts unrelated to PCOS among situations requiring avoidance or specialist assessment. A possible pregnancy should be excluded before a new treatment course begins.
Clomifene is generally used in defined courses, so a taper is not normally the same issue as stopping a daily corticosteroid or antidepressant. Hormonal effects may decline after treatment, while ovulation or testosterone production may return toward the person’s underlying baseline. The EMA states in its 2023 product information that follow-up depends on the indication, response and adverse effects, so repeat courses should not be started without a clinical plan.
Older age does not create a standard automatic dose, but it increases the importance of reviewing liver function, visual health, cardiovascular risk and other medicines. NICE fertility guidance from 2024 would support individual assessment rather than applying a routine fertility protocol outside its intended population. Male endocrine treatment in an older adult also requires confirmation of the cause of low testosterone and a clear fertility goal.
Clomifene tablets can generally be taken with food or without food, provided the same approach is used consistently during the prescribed course. The MHRA product information from 2024 focuses on the prescribed regimen and adverse-effect monitoring rather than requiring a special meal pattern. Taking the tablet with food may feel easier for someone who develops nausea, while visual symptoms or severe abdominal pain require medical assessment rather than a change in meal timing.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
I had PCOS and irregular cycles. The first course gave me headaches and hot flushes, but the cycle became easier to track. The clinic used blood tests rather than relying on symptoms alone.
Birmingham One cycle 30 Sept 2026My testosterone result improved after several weeks, but I felt more irritable and had trouble sleeping. The endocrinology team reduced the uncertainty by checking several hormones instead of focusing on one number.
Glasgow Several weeks 9 Oct 2026I had taken anabolic steroids before starting treatment and did not initially mention them. My first blood results were difficult to interpret. Once the full history was recorded, the plan became clearer.
Stoke-on-Trent Several weeks 14 Oct 2026I noticed flashing lights after a dose and stopped taking further tablets until I received urgent advice. The symptom settled, but it changed how seriously I treated the warning information.
Nottingham One dose 27 Oct 2026
